Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Total Liabilities (2016 - 2025)

United Therapeutics' Total Liabilities history spans 17 years, with the latest figure at $783.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 14.8% year-over-year to $783.8 million; the TTM value through Dec 2025 reached $783.8 million, down 14.8%, while the annual FY2025 figure was $783.8 million, 14.8% down from the prior year.
  • Total Liabilities for Q4 2025 was $783.8 million at United Therapeutics, up from $760.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.3 billion in Q3 2023 and bottomed at $734.4 million in Q2 2025.
  • The 5-year median for Total Liabilities is $1.2 billion (2021), against an average of $1.1 billion.
  • The largest annual shift saw Total Liabilities grew 10.97% in 2021 before it dropped 28.42% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $1.2 billion in 2021, then rose by 3.11% to $1.2 billion in 2022, then decreased by 5.26% to $1.2 billion in 2023, then fell by 22.18% to $920.0 million in 2024, then decreased by 14.8% to $783.8 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Total Liabilities are $783.8 million (Q4 2025), $760.9 million (Q3 2025), and $734.4 million (Q2 2025).